2024
High p16INK4A expression in glioblastoma is associated with senescence phenotype and better prognosis
Park S, Roh T, Tanaka Y, Kim Y, Park S, Kim T, Eom S, Park T, Park I, Kim S, Kim J. High p16INK4A expression in glioblastoma is associated with senescence phenotype and better prognosis. Neoplasia 2024, 60: 101116. PMID: 39724755, PMCID: PMC11729681, DOI: 10.1016/j.neo.2024.101116.Peer-Reviewed Original ResearchConceptsP16<sup>INK4a</sup> expressionImmune cell infiltrationTumor cellsCell infiltrationImmunologically active tumor microenvironmentInfiltration of T cellsActive tumor microenvironmentTERT promoter mutationsExtended overall survivalIsocitrate dehydrogenase (IDH)-wildtypeSecretion of chemokinesSenescent phenotypeMalignant brain tumorsIn vitro studiesEGFR amplificationOverall survivalTumor microenvironmentCDKN2A/2B deletionT cellsPrognostic markerImprove prognosisP16INK4A expressionPromoter mutationsTumorBrain tumors
2023
Ventricular Arrhythmia in Cancer Patients: Mechanisms, Treatment Strategies and Future Avenues
Agarwal M, Sridharan A, Pimentel R, Markowitz S, Rosenfeld L, Fradley M, Yang E. Ventricular Arrhythmia in Cancer Patients: Mechanisms, Treatment Strategies and Future Avenues. Arrhythmia & Electrophysiology Review 2023, 12: e16. PMID: 37457438, PMCID: PMC10345968, DOI: 10.15420/aer.2023.04.Peer-Reviewed Original ResearchVentricular arrhythmiasCancer treatmentOverall care of patientsCare of patientsInterruption of cancer treatmentNovel cancer treatmentsOverall careQTc prolongationCardiovascular complicationsImprove prognosisRepolarisation abnormalitiesVentricular conductionTreatment strategiesCancer patientsCancer therapyCardiovascular diseaseCancerArrhythmiasPatientsTreatmentQTcComplicationsPrognosis
2022
Pharmacological targeting of androgen receptor elicits context-specific effects in estrogen receptor-positive breast cancer
Wei L, Gao H, Yu J, Zhang H, Nguyen T, Gu Y, Passow M, Carter J, Qin B, Boughey J, Goetz M, Weinshilboum R, Ingle J, Wang L. Pharmacological targeting of androgen receptor elicits context-specific effects in estrogen receptor-positive breast cancer. Cancer Research 2022, 83: 456-470. PMID: 36469363, PMCID: PMC9896025, DOI: 10.1158/0008-5472.can-22-1016.Peer-Reviewed Original ResearchConceptsER+ breast cancerAR-targeted therapiesBreast cancer modelAndrogen receptorBreast cancerAR agonistsCancer modelsAR/ER ratioEstrogen receptor-positive breast cancerReceptor-positive breast cancerAssociated with improved prognosisAR-targeted drugsAlterations of global gene expressionRelationship of ARBinding of ARER+ tumorsAR expressionCell growth inhibitionAR signalingImprove prognosisEstrogen receptorER levelsTumor growthTreatment strategiesEnz treatment
2018
MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer
Gawrzak S, Rinaldi L, Gregorio S, Arenas E, Salvador F, Urosevic J, Figueras-Puig C, Rojo F, del Barco Barrantes I, Cejalvo J, Palafox M, Guiu M, Berenguer-Llergo A, Symeonidi A, Bellmunt A, Kalafatovic D, Arnal-Estapé A, Fernández E, Müllauer B, Groeneveld R, Slobodnyuk K, Stephan-Otto Attolini C, Saura C, Arribas J, Cortes J, Rovira A, Muñoz M, Lluch A, Serra V, Albanell J, Prat A, Nebreda A, Benitah S, Gomis R. MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer. Nature Cell Biology 2018, 20: 211-221. PMID: 29358704, DOI: 10.1038/s41556-017-0021-z.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnimalsBiomarkers, TumorBone NeoplasmsBreast NeoplasmsCell DifferentiationChromatinFemaleGATA3 Transcription FactorGene Expression Regulation, NeoplasticGenome, HumanHepatocyte Nuclear Factor 3-alphaHumansMiceMiddle AgedNeoplasm MetastasisPrognosisReceptors, EstrogenRibosomal Protein S6 Kinases, 90-kDaRNA, Small InterferingXenograft Model Antitumor AssaysConceptsER+ breast cancerLuminal cell differentiationBreast cancerMetastatic dormancyProgression of ER+ breast cancerDifferentiation of breast cancer cellsGenome-wide short hairpin RNA screenSymptomatic bone metastasesEstrogen receptor-positiveShort hairpin RNA screenMSK1 expressionBreast cancer cellsCell differentiationFOXA1 transcription factorMetastatic latencyReceptor-positiveEarly relapseBone metastasesYears of latencyBone homingStratify patientsExpression of genesMicrometastatic lesionsImprove prognosisMetastatic progression
2016
Diagnosing colorectal medullary carcinoma: interobserver variability and clinicopathological implications
Lee L, Yantiss R, Sadot E, Ren B, Calvacanti M, Hechtman J, Ivelja S, Huynh B, Xue Y, Shitilbans T, Guend H, Stadler Z, Weiser M, Vakiani E, Gönen M, Klimstra D, Shia J. Diagnosing colorectal medullary carcinoma: interobserver variability and clinicopathological implications. Human Pathology 2016, 62: 74-82. PMID: 28034727, PMCID: PMC5392420, DOI: 10.1016/j.humpath.2016.12.013.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorBiopsyCarcinoma, MedullaryCell DifferentiationColorectal NeoplasmsDNA Mismatch RepairDNA Repair EnzymesFemaleHumansImmunohistochemistryMaleMiddle AgedObserver VariationPredictive Value of TestsPrognosisReproducibility of ResultsTerminology as TopicYoung AdultConceptsMedullary carcinomaDiagnosis of medullary carcinomaGroup 3World Health Organization criteriaDiagnose medullary carcinomaSpectrum of histologyHistological subtypesMedullary tumorsMismatch repair deficiencyPrognostic relevanceMismatch repair protein deficiencyOrganization criteriaImproved survivalImprove prognosisClinicopathological implicationsGastrointestinal pathologistsInterobserver agreementMorphologic spectrumColorectal adenocarcinomaInterobserver variabilityGroup 1CarcinomaMolecular pathogenesisWorld Health OrganizationProtein deficiency
2012
Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer
Bolton K, Trench G, Goh C, Sadetzki S, Ramus S, Karlan B, Lambrechts D, Despierre E, Barrowdale D, McGuffog L, Healey S, Easton D, Sinilnikova O, Benítez J, García M, Neuhausen S, Gail M, Hartge P, Peock S, Frost D, Evans D, Eeles R, Godwin A, Daly M, Kwong A, K. E, Lázaro C, Blanco I, Montagna M, D'Andrea E, Nicoletto M, Johnatty S, Kjær S, Jensen A, Høgdall E, Goode E, Fridley B, Loud J, Greene M, L. P, Chetrit A, Lubin F, Hirsh-Yechezkel G, Glendon G, Andrulis I, Toland A, Senter L, Gore M, Gourley C, Michie C, Song H, Tyrer J, Whittemore A, McGuire V, Sieh W, Kristoffersson U, Olsson H, Borg Å, Levine D, Steele L, Beattie M, Chan S, Nussbaum R, Moysich K, Gross J, Cass I, Walsh C, Li A, Leuchter R, Gordon O, Garcia-Closas M, Gayther S, Chanock S, Antoniou A, Pharoah P, Investigators A. Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer. JAMA 2012, 307: 382-389. PMID: 22274685, PMCID: PMC3727895, DOI: 10.1001/jama.2012.20.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancerInvasive epithelial ovarian cancerBRCA2 carriersOvarian cancerGermline mutationsOverall survivalInvasive EOCEpithelial ovarian cancer casesEffect of BRCA1BRCA2 mutation carriersSurvival of womenYear of diagnosisPathogenic germline mutationsBRCA1 carriersBRCA2 mutationsBRCA carriersFavorable survivalImprove prognosisSurvival differencesMutation carriersBRCA2Pooled analysisBRCA1Observational studyCancer
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply